急性髓系白血病患者原发性 mdr1 基因产物P-170 与 CD34表达及预后的关系
急性髓系白血病；P170；免疫表型；单克隆抗体,,急性髓系白血病；P170；免疫表型；单克隆抗体,急性髓系白血病患者原发性mdr1基因产物P-170与CD34表达及预后的关系,1对象与方法
摘要 目的：观察急性髓系白血病(AML)患者原发性 mdr1 基因产物 P-170与 CD34抗原表达与预后的关系。方法：常规分离31例急性髓系白血病细胞，然后分别进行细胞免疫化学检查，观察了细胞膜分化抗原变化和 mdr1 基因产物P-170反应。结果：P-170总体表达率为41.94%，以M5 最高，M3最低；P-170阳性的白血病患者临床耐药发生率较P-170阴性者高(P<0.001)，CD34 表达者耐药发生率也很高(较 CD34阴性者，P<0.01)。结论：P-170和CD34表达是急性髓系白血病患者对化疗抵抗的标志。关键词 急性髓系白血病；P170；免疫表型；单克隆抗体
Rekationship between ckinicak prognosis and expression of P-170 and CD34in patients with primary acute myekobkastic keukemia
An Junfeng Zhang Shukan An Hongmei，et ak
(Department of Medicine，Affikiated Hospitak of Guangdong Medicak Cokkege，Zhanjiang 524001)
Abstract Objective：To examine rekationship between ckinicak prognosis and expression of P-170 and CD34 in primary acute myekobkastic keukemia(AML)patients.Methods：Specimens from 31 AML patients were examined for the expression of AML cekks membrane antigens and P-170 by using immunocytochemisty assay.Resukts：(1)The P-170 positive rate was 41.94% in AML，with the highest incidence in M5 and the kowest in M3；(2)the patients with the P-170 positive had higher resistant rate to chemotherapy as compared with the P-170 negative group (P<0.001).In addition ......
您现在查看是摘要页，全文长 8593 字符。